• Herbal Extracts Delay Precocious Puberty in Danazol Rat Mode

  2026-06-12

  The referenced study demonstrates that a complex of Eclipta prostrata and Hordeum vulgare extracts can delay the onset of precocious puberty in rat models induced by Danazol and high-fat diet. These findings highlight a potential natural alternative for modulating the hypothalamic–pituitary–gonadal axis, offering new directions in puberty research.

• Cannabis Terpenes Alleviate Neuropathic Pain via A2A Recepto

  2026-06-12

  Schwarz et al. reveal that specific terpenes from Cannabis sativa produce significant antinociceptive effects in mouse models of chronic neuropathic pain through activation of adenosine A2A receptors, rather than canonical cannabinoid pathways. This mechanistic insight advances the field by highlighting non-cannabinoid, non-rewarding analgesic strategies with translational potential for pain research.

• Murine Recombinant PDGF-BB: Precision in Vascular Cell Proli

  2026-06-11

  Murine recombinant PDGF-BB unlocks advanced modeling of smooth muscle and connective tissue cell proliferation, crucial for dissecting vascular remodeling mechanisms in disease. This guide details optimal workflows, troubleshooting strategies, and insights from the latest metabolic-epigenetic research, making it a cornerstone for next-generation pulmonary hypertension and vascular biology studies.

• AMD-070 Hydrochloride: Applied Use Cases for the CXCR4 Antag

  2026-06-11

  Mavorixafor hydrochloride (AMD-070 hydrochloride) from APExBIO empowers researchers to dissect the CXCR4/CXCL12 axis with precision, driving breakthroughs in anti-HIV research, hematopoietic modeling, and rare immunodeficiency workflows. This guide details practical protocols, troubleshooting tips, and comparative advantages for integrating this potent and selective CXCR4 antagonist into diverse experimental frameworks.

• (+)-Bicuculline: Technical Guidance for GABAA Receptor Antag

  2026-06-10

  (+)-Bicuculline is a classical GABAA receptor antagonist used in neuroscience research to dissect GABAergic signaling pathways and modulate synaptic NMDA receptor activity. It is not suitable for diagnostic, clinical, or therapeutic applications. Careful adherence to solubility and storage parameters is essential for reproducible results.

• ATRX Loss Sensitizes High-Grade Glioma to RTK/PDGFR Inhibito

  2026-06-10

  The reference study demonstrates that high-grade glioma cells deficient in ATRX are significantly more sensitive to receptor tyrosine kinase and PDGFR inhibitors. This work reveals a promising direction for stratified therapeutic approaches and highlights the importance of assessing ATRX status in both preclinical research and clinical trials involving RTK inhibitors.

• RRP Extracts Restore Hepatic Lipid Metabolism in Liver IRI

  2026-06-09

  The referenced study elucidates how Radix Rehmanniae Praeparata (RRP) extracts ameliorate hepatic ischemia-reperfusion injury (HIRI) by modulating hepatocyte lipid metabolism. By targeting AMPK activation, SREBP2 inhibition, and LXRα-mediated cholesterol efflux, the study reveals detailed molecular mechanisms underlying RRP's hepatoprotective effects, providing new directions for experimental and translational research on liver injury.

• Ziprasidone Hydrochloride: Mechanistic Precision in Dopamine

  2026-06-09

  Explore the multifaceted roles of Ziprasidone Hydrochloride in neuroscience and cancer metabolism research. This in-depth analysis reveals mechanistic nuances, impurity insights, and advanced applications for translational scientists.

• Applied Workflows with EZ Cap™ Cy5 EGFP mRNA (5-moUTP)

  2026-06-08

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) integrates dual fluorescence and immune-evasive chemistry to streamline mRNA delivery and translation efficiency studies. Its Cy5 labeling and 5-moUTP modification empower direct, quantifiable tracking and robust functional assays, setting a new benchmark for gene delivery optimization.

• CXCR4-Targeted Theranostics in Lymphoma: Imaging and Therapy

  2026-06-08

  This review details recent innovations in the use of CXCR4-targeted imaging ligands and antagonists for lymphoma, emphasizing their dual diagnostic and therapeutic value. The integration of molecular imaging with CXCR4 inhibition enables improved disease characterization and personalized treatment strategies, though clinical translation faces challenges related to off-target effects and compensatory pathways.

• GS-441524 Prodrug Pathways: Translational Antiviral Strategy

  2026-06-07

  Explore the mechanistic foundations and translational impact of GS-441524 prodrugs in antiviral research. This article bridges cutting-edge LC–MS/MS mapping, protocol optimization, and strategic considerations for researchers advancing anti-SARS-CoV-2 nucleoside analogs from bench to bedside.

• Cannabis Terpenes Relieve Neuropathic Pain via A2A Receptors

  2026-06-06

  Schwarz et al. demonstrate that specific terpenes from Cannabis sativa produce robust antinociceptive effects in mouse models of chronic neuropathic pain through activation of adenosine A2A receptors, rather than cannabinoid pathways. This mechanistic insight opens new directions for non-rewarding pain therapeutics and clarifies the distinct pharmacology of terpenes compared to cannabinoid receptor modulators.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Te

  2026-06-05

  DiI (DiIC18(3)) is a lipophilic orange fluorescent probe enabling high-contrast, specific labeling of plasma membranes in live and fixed cell or tissue workflows. It is not suitable for water-based protocols or for labeling intracellular organelles. Adhering to solvent compatibility and workflow-specific parameters is critical for reliable and selective membrane staining.

• Okadaic acid (A4540): Protocols for Protein Phosphatase 1 In

  2026-06-05

  Okadaic acid is a nanomolar-potency protein phosphatase 1 inhibitor, ideal for dissecting phosphorylation-dependent cellular processes in apoptosis and signal transduction research. It should be used where selective and potent inhibition of PP1/PP2A is required, but not in experiments where off-target phosphatase effects or solvent interference could confound results.

• Cardiovascular Outcomes with Ertugliflozin: Implications for

  2026-06-04

  The VERTIS CV trial rigorously assessed the cardiovascular safety of ertugliflozin in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. While ertugliflozin demonstrated noninferiority to placebo for major adverse cardiovascular events, its secondary benefits for heart failure and renal outcomes were less pronounced, highlighting nuances in SGLT2 inhibitor therapy selection and comparative model design.

16664 records 1/1111 page Next 12345 下5页 Last page